CYBERSPRINT
10.10.2019 08:02:08 CEST | Business Wire | Press release
Cybersprint, the European leader in Digital Risk Protection, announced that it has won the 2019 Cyber Defense Global Award for their innovative Digital Footprint Security. These Global Awards are specifically focused on finding innovative infosec players with a presence outside of the USA and/or with a more global focus. Cybersprint is honoured to be selected.
“With cybercrime heading into billions of records stolen and potentially trillions of dollars in damages, we are proud to recognize Cybersprint as an award-winning innovator that offers a new approach to defeat these criminals,” said Pierlugi Paganini, editor-in-chief, Cyber Defense Magazine.
Cybersprint’s innovative Digital Risk Protection platform
Cybersprint has developed a unique Digital Risk Protection (DRP) SaaS platform that automatically maps, monitors and manages online risks to an organisation over a broad range of digital channels, such as the Web, Social Media, Mobile Apps and even the Deep Web. The DRP platform works with the same techniques that hackers use in search of online vulnerabilities, only Cybersprint automates and combines them with a large variety of approaches, sources and applications. After entering the brand or organisation’s name, it reveals the digital attack surface consisting of the online entry points related to the brand and the associated digital risks. By combining all these data and using AI, Big Data, and data visualisation techniques, Cybersprint provides its customers with clear and actionable insights into the unknown and invisible digital risks and protects the organisation’s Digital Footprint.
Pieter Jansen, CEO and founder of Cybersprint: “The massively increasing digitalisation provides hackers with more opportunities to carry out successful attacks. Our Digital Risk Protection platform enables our clients to monitor and detect digital risks interfering with their online security in real-time. Digital vulnerabilities can quickly be found and resolved to stay ahead of the attackers.”
Many organisations in Europe already use Cybersprint’s DRP SaaS platform, including global banks, insurance companies, governments, large municipalities, renowned retail brands, and critical infrastructure companies. Cybersprint takes pride in its customer base. For more information: www.cybersprint.com
About the Cyber Defense Global Awards
This is the Cyber Defense Magazine's seventh year of honouring InfoSec innovators from around the globe. With over 3,000 cyber security companies worldwide, only a small number, fewer than 200, are highlighted as Global Awards winners, based upon independent judging and analysis. You’ll find winners from all over the Globe including Australia, China, Israel, India, Italy, Malta, the Netherlands, New Zealand, the United Kingdom and the USA. Learn more at www.cyberdefenseawards.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005725/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom